The role of inflammation in the pathogenesis of cardiovascular morbidity in patients with acromegaly - Inflammation and cardiovasculair morbidity in acromegaly

Radboud Universitair Medisch Centrum0 个研究点目标入组 240 人开始时间: 待定最近更新: 2024年4月23日

适应症

试验速览

暂无简介。

•Biochemically confirmed diagnosis of acromegaly by an increased IGF-1 level (e.i. mean > 2 standard deviations (SD) for age and sex) and an insufficient suppression of serum GH levels (e.i. GH *1 mU/l) during an oral glucose tolerance test (OGTT).

•Excluded from participation in this study will be subjects who are/have:
•* Mentally incompetent;
•* Pregnant or breastfeeding;
•* Inadequately supplied, unstable or untreated hormonal deficiencies;
•* Known inflammatory or infectious diseases or an immunosuppressive status;
•* Using hormonal therapy: hormonal contraceptives (42) or hormonal substitution therapy (only applicable for the subgroups of patients);
•* Using medication interfering with adiponectines, such as thiazolidinediones;
•* Severe comorbidities: active malignancy (except for basal cell carcinoma), serious psychiatric pathology;
•* A systolic blood pressure *160 mmHg and/or a diastolic blood pressure *100 mmHg;
•* Known untreated or unstable diabetes mellitus or ischemic cardiovascular disease;
•* A self-reported alcohol consumption of >21 units per week.

发起方